Disease · MONDO_0012817
Ewing sarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Ewing sarcoma. Diseases, record MONDO_0012817. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0012817
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- ES, Ewing family tumor, Ewing's family localised tumour, Ewing's family localized tumor, Ewing's sarcoma, Ewing's tumor, Ewing's tumour, Ewings sarcoma, PNET of Thoracopulmonary region
- Open Targets
Drugs130
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 32 | 32 | 32 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 24 | 24 | 24 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 24 | 24 | 24 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 19 | 19 | 19 | Drugs and targets |
| IFOSFAMIDE | CHEMBL1024 | Small molecule | Phase 3 | ClinicalTrials.gov | 19 | 19 | 19 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 18 | 18 | 18 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 3 | ClinicalTrials.gov | 18 | 18 | 17 | Drugs and targets |
| TOPOTECAN | CHEMBL84 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| BUSULFAN | CHEMBL820 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| MELPHALAN | CHEMBL852 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
1 to 10 of 130
See all 130 drugsTargets212
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 212
See all 212 targetsTrials149
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01231906 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | Phase 3 | 642 | 2021-05-04 | Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues | CYCLOPHOSPHAMIDE, TOPOTECAN HYDROCHLORIDE, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02454972 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Phase 2 | 345 | 2021-11-22 | Advanced Solid Tumors | LURBINECTEDIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00642941 | A Study of R1507 in Participants With Recurrent or Refractory Sarcoma | Phase 2 | 317 | 2021-02-03 | Sarcoma | TEPROTUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | Phase 3 | 312 | 2022-07-01 | Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE PHOSPHATE, GANITUMAB, IFOSFAMIDE, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Phase 2 | 267 | 2025-03-11 | Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Renal Medullary Carcinoma, Epithelioid Sarcoma, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation | DOXORUBICIN, TAZEMETOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00617890 | A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) | Phase 2 | 219 | 2015-12-11 | Osteosarcoma, Sarcoma, Ewing's, Peripheral Neuroectodermal Tumor | ROBATUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Phase 1/2 | 140 | 2023-01-10 | Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00560235 | Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors | Phase 1/2 | 138 | 2014-02-28 | Ewing's Sarcoma Family of Tumors | FIGITUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04447755 | A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) | Phase 2 | 127 | 2023-10-04 | Relapsed or Refractory Solid Tumors | LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | Phase 2 | 118 | 2017-06-05 | Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma | ALISERTIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 149
See all 149 trialsComparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A (Combination Chemotherapy) vs Arm B (Combination Chemotherapy, Topotecan Hydrochloride): deaths from any cause | 51 of 308 | 42 of 318 | 626 | NCT01231906 | Trial comparisons |
| Arm A (Combination Chemotherapy) vs Arm B (Combination Chemotherapy, Topotecan Hydrochloride): serious adverse events | 8 of 308 | 11 of 318 | 626 | NCT01231906 | Trial comparisons |
| Regimen A (VDC/IE) vs Regimen B (VDC/IE + Ganitumab): deaths from any cause | 61 of 145 | 67 of 150 | 295 | NCT02306161 | Trial comparisons |
| Regimen A (VDC/IE) vs Regimen B (VDC/IE + Ganitumab): serious adverse events | 3 of 145 | 45 of 150 | 295 | NCT02306161 | Trial comparisons |
| Osteosarcoma vs Ewing Sarcoma: Incidence of Adverse Events | 45 of 45 | 45 of 45 | 90 | NCT02243605 | Trial comparisons |
| Osteosarcoma vs Ewing Sarcoma: deaths from any cause | 42 of 45 | 37 of 45 | 90 | NCT02243605 | Trial comparisons |
| Osteosarcoma vs Ewing Sarcoma: serious adverse events | 30 of 45 | 31 of 45 | 90 | NCT02243605 | Trial comparisons |
| Abemaciclib + Irinotecan +Temozolomide vs Irinotecan +Temozolomide: deaths from any cause | 15 of 30 | 8 of 16 | 46 | NCT05440786 | Trial comparisons |
| Arm A: VACdxr With ImmTher vs Arm B: VACdxr: serious adverse events | 1 of 31 | 0 of 14 | 45 | NCT00038142 | Trial comparisons |
| Abemaciclib + Irinotecan +Temozolomide vs Irinotecan +Temozolomide: serious adverse events | 12 of 30 | 5 of 15 | 45 | NCT05440786 | Trial comparisons |
1 to 10 of 25
See all 25 comparisons in its trialsPapers from its trials93
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0012817
GET https://conductscience.org/api/diseases/v1/MONDO_0012817/drugs?page=2